Sudeep Pharma Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 22 May 2026

Company page: Sudeep Pharma share price, financials & guidance record

Sudeep Pharma Limited reported a strong FY26 with 27.9% revenue growth and 25.7% PAT growth, driven by robust performance in its Specialty Ingredients segment. The company made significant strategic progress including a greenfield expansion and the groundbreaking of a battery materials project. However, EBITDA margins saw a slight compression, and working capital days increased, which management aims to normalize in the coming year.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue down 23.8%, net profit down 21.2% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	149	83	105	80	88 −41%	90 +8%	80 −24%
Expenses	85	57	59	50	57	61	51
EBITDA	63	26	45	30	31 −51%	30 +15%	29 −36%
Margin	43%	32%	43%	38%	35%	33%	36%
Other income	2	2	3	7	13	9	10
Interest	1	1	2	1	2	1	2
Depreciation	3	2	2	2	2	2	2
Profit before tax	62	26	45	34	40 −35%	37 +42%	35 −22%
Tax rate	21%	21%	27%	26%	25%	27%	26%
Net profit	49	21	33	25	30 −39%	27 +29%	26 −21%
EPS	128.13	2.12	3.41	2.59	3.06	2.38	2.28

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls